Symberix Featured in Scientific American
Article on Pharmacomicrobiomics

 Symberix Featured in Scientific American Article

Durham, NC (January 1, 2020) - An article in Scientific American highlights Symberix's work in the emerging field of “pharmacomicrobiomics” -- the study of how microbes impact drug disposition, efficacy, and toxicity. Symberix is developing bacteria-targeted small molecules that prevent the GI toxicity of many common medications, including nonsteroidal anti-inflammatory drugs and irinotecan.

“If [Symberix co-founder] Redinbo and his colleagues succeed, they will have opened the door to a class of drugs that can modify microbes with great precision.” Read the full Scientific American article here.

Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI disorders. Gut microbes express numerous proteins, including a family of bacterial β-glucuronidase enzymes capable of generating toxic metabolites of many common medications in the lower GI tract. Symberix is developing bacterial β-glucuronidase inhibitors as adjunctive therapy to mitigate drug-induced toxicities and is exploring their use as monotherapy for other lower GI disorders, such as inflammatory bowel disease. Symberix’s internal team and external advisors have a deep understanding of the biology of the gut microbiome, and extensive drug discovery and clinical development experience.

Contact:
Greg Mossinghoff
Chief Business Officer
Symberix, Inc.
Greg.Mossinghoff@Symberix.com